Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.

IF 1.4 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Zeitschrift fur Gastroenterologie Pub Date : 2024-01-01 Epub Date: 2024-01-09 DOI:10.1055/a-2207-5519

Christoph Schramm, Ayaz Sapuk, Dieter Hoyer, Sonia Radünz, Hartmut Schmidt

{"title":"Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.","authors":"Christoph Schramm, Ayaz Sapuk, Dieter Hoyer, Sonia Radünz, Hartmut Schmidt","doi":"10.1055/a-2207-5519","DOIUrl":null,"url":null,"abstract":"Background: Patients with primary sclerosing cholangitis (PSC) carry increased risks for malignancy, among which cholangiocarcinoma (CCA) is the most frequent. We aimed to characterise a cohort of patients with PSC and intrahepatic CCA (iCCA) and to compare this cohort with CCA in different localisations.Methods: We performed a retrospective analysis of our medical database from 01.01.2007 to 30.06.2023 and differentiated CCA according to its localisation within the biliary tract into iCCA, perihilar CCA (pCCA), distal CCA (dCCA), and gallbladder carcinoma (GBC).Results: We identified 8 (28%) patients with iCCA, 14 (48%) patients with pCCA, 6 (21%) patients with GBC, and 1 (3%) patient with dCCA without significant differences in gender distribution and mean age. Mean time between diagnosis of PSC and CCA was 158±84 months for iCCA, 93±94 months for pCCA, and 77±69 months for GBC (p=0.230). At the time of CCA diagnosis, advanced-stage disease was present in 6 (75%) patients with iCCA, 13 (93%) patients with pCCA, and 2 (40%) patients with GBC (p=0.050). Only 5 (63%) patients with iCCA received curatively intended surgery, of whom 4 (80%) patients developed recurrence after a mean time of 38±31 months. Mean survival time in patients with iCCA (35±33 months) lay between patients with pCCA (14±8 months) and patients with GBC (57±58 months), but the difference was not statistically significant (p=0.131).Conclusion: Patients with PSC and iCCA showed an advanced tumour stage at diagnosis and limited long-time survival, which was classified between pCCA with worse prognosis and GBC with better prognosis.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur Gastroenterologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2207-5519","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with primary sclerosing cholangitis (PSC) carry increased risks for malignancy, among which cholangiocarcinoma (CCA) is the most frequent. We aimed to characterise a cohort of patients with PSC and intrahepatic CCA (iCCA) and to compare this cohort with CCA in different localisations.

Methods: We performed a retrospective analysis of our medical database from 01.01.2007 to 30.06.2023 and differentiated CCA according to its localisation within the biliary tract into iCCA, perihilar CCA (pCCA), distal CCA (dCCA), and gallbladder carcinoma (GBC).

Results: We identified 8 (28%) patients with iCCA, 14 (48%) patients with pCCA, 6 (21%) patients with GBC, and 1 (3%) patient with dCCA without significant differences in gender distribution and mean age. Mean time between diagnosis of PSC and CCA was 158±84 months for iCCA, 93±94 months for pCCA, and 77±69 months for GBC (p=0.230). At the time of CCA diagnosis, advanced-stage disease was present in 6 (75%) patients with iCCA, 13 (93%) patients with pCCA, and 2 (40%) patients with GBC (p=0.050). Only 5 (63%) patients with iCCA received curatively intended surgery, of whom 4 (80%) patients developed recurrence after a mean time of 38±31 months. Mean survival time in patients with iCCA (35±33 months) lay between patients with pCCA (14±8 months) and patients with GBC (57±58 months), but the difference was not statistically significant (p=0.131).

Conclusion: Patients with PSC and iCCA showed an advanced tumour stage at diagnosis and limited long-time survival, which was classified between pCCA with worse prognosis and GBC with better prognosis.

查看原文本刊更多论文

肝内胆管癌和原发性硬化性胆管炎患者的肿瘤分期和总生存期--一项回顾性队列研究。

背景：原发性硬化性胆管炎（PSC）患者罹患恶性肿瘤的风险增加，其中以胆管癌（CCA）最为常见。我们的目的是描述一组 PSC 和肝内 CCA（iCCA）患者的特征，并将这组患者与不同部位的 CCA 进行比较：我们对 2007 年 1 月 1 日至 2023 年 6 月 30 日的医疗数据库进行了回顾性分析，并根据 CCA 在胆道内的定位将其分为 iCCA、肝周 CCA（pCCA）、远端 CCA（dCCA）和胆囊癌（GBC）：我们发现了 8 名（28%）iCCA 患者、14 名（48%）pCCA 患者、6 名（21%）GBC 患者和 1 名（3%）dCCA 患者，他们的性别分布和平均年龄无明显差异。PSC 和 CCA 诊断之间的平均时间为：iCCA 158±84 个月，pCCA 93±94 个月，GBC 77±69 个月（P=0.230）。在确诊 CCA 时，6 名 iCCA 患者（75%）、13 名 pCCA 患者（93%）和 2 名 GBC 患者（40%）处于疾病晚期（P=0.050）。只有 5 名（63%）iCCA 患者接受了治愈性手术，其中 4 名（80%）患者在平均 38±31 个月后复发。iCCA患者的平均生存时间（35±33个月）介于pCCA患者（14±8个月）和GBC患者（57±58个月）之间，但差异无统计学意义（P=0.131）：结论：PSC 和 iCCA 患者确诊时肿瘤分期较晚，长期生存期有限，pCCA 患者预后较差，GBC 患者预后较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Zeitschrift fur Gastroenterologie 医学-胃肠肝病学

CiteScore

1.40

自引率

15.40%

发文量

562

审稿时长

6-12 weeks

期刊介绍： Die Zeitschrift für Gastroenterologie ist seit über 50 Jahren die führende deutsche Fachzeitschrift auf dem Gebiet der Gastroenterologie. Sie richtet sich an Gastroenterologen und alle anderen gastroenterologisch interessierten Ärzte. Als offizielles Organ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten sowie der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie informiert sie zuverlässig und aktuell über die wichtigen Neuerungen und Entwicklungen in der Gastroenterologie.